TSPO expression in a wide diversity of neurologic and neurodegenerative diseases has been monitored by PET with a large variety of first generation ([11C](R)-PK11195) [6] or second and third generation of radioligands such as [11C] SSR180575 [7], [18F] PBR28 [8, 9], [11C] DAA1106 [10–12], [11C] CLINME [13], [18F] FEAC [14], [18F] FEDAC [14], [18F] FEPPA [15, 16], [18F] DPA-714 [3, 17, 18], [18F] PBR111 [8], [18F] PBR06 [19, 20], and [18F] GE-180 [21–23], among others, evidencing the interest aroused by TSPO imaging from the bench to the bedside. The gene discussed is TSPO; the disease is neurodegenerative disease.